Natco Pharma Limited (NATCOPHARM)
ISIN: INE987B01026 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
654.8
7.45(1.15%)

NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Pricing Updates

TODAY'S HIGH

663.95

TODAY'S LOW

646.05

52 WEEK HIGH

993.95

52 WEEK LOW

607.75

Major Holders

% of Shares Held by
All Insider

51.38%

% of Shares Held by
Institutions

19.89%

% of Float Held by
Institutions

40.92%

Number of Institutions
Holding Shares

50

Company Overview

MARKET CAP

11953.83 Cr.

ETERPRISE VALUE

11433.88 Cr.

NO. OF SHARES

18.25 Cr.

BOOK VALUE

233.865

DIV. YIELD

3.5%

DEBT

415.50 Cr.

GROSS PROFIT

1823.90 Cr.

CASH

799.90 Cr.

REVENUE

2419.10 Cr.

REVENUE/SHARE

132.609

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments203.90 Cr.36.20 Cr.82.10 Cr.-218.70 Cr.
Change To Liabilities7.40 Cr.-109.50 Cr.41.70 Cr.-51.20 Cr.
Total cashflows from Investing Activities-5.30 Cr.-103.30 Cr.-167 Cr.-612.20 Cr.
Net Borrowings135.80 Cr.-49.60 Cr.-80.90 Cr.213.10 Cr.
Total Cash from Financing Activities34.80 Cr.-185.70 Cr.-250.80 Cr.-50.90 Cr.
Other Liabilities-56.30 Cr.6.20 Cr.-56.60 Cr.11.60 Cr.
Total Assets010 Lakhs47.50 Cr.47.50 Cr.
Net Income170 Cr.440.90 Cr.460.80 Cr.644.40 Cr.
Change in Cash85.30 Cr.6 Cr.-8.50 Cr.6.60 Cr.
Effect of Exchange Rate9.30 Cr.-3.80 Cr.-8 Cr.90 Lakhs
Total Cash from Operating Activities46.50 Cr.298.80 Cr.417.30 Cr.668.80 Cr.
Depreciation142.60 Cr.114.50 Cr.97.30 Cr.78.70 Cr.
Other Cashflows from Investing Activities82.30 Cr.67.10 Cr.87.40 Cr.52.40 Cr.
Dividends Paid-82.20 Cr.-113.90 Cr.-127.40 Cr.-91.90 Cr.
Change to Inventory56.40 Cr.-240.20 Cr.-28.90 Cr.-90.60 Cr.
Change to Account Receivables-238.90 Cr.130.60 Cr.-53.80 Cr.138.80 Cr.
Other Cashflows from Financing Activities-18.80 Cr.-22.30 Cr.-36.40 Cr.-37.40 Cr.
Change to Net Income-34.70 Cr.-46.10 Cr.-45.70 Cr.-65.20 Cr.
Capital Expenditures-232.70 Cr.-254.60 Cr.-355.70 Cr.-456.60 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax202.20 Cr.579.60 Cr.568.70 Cr.824.70 Cr.
Minority Interest01.80 Cr.11.20 Cr.2 Cr.
Net Income120.90 Cr.493.30 Cr.485.70 Cr.716 Cr.
Selling General Administrative444.80 Cr.439 Cr.471.90 Cr.444.60 Cr.
Gross Profit1383.90 Cr.1524.30 Cr.1509 Cr.1712.70 Cr.
Ebit120.90 Cr.493.30 Cr.485.70 Cr.716 Cr.
Operating Income120.90 Cr.493.30 Cr.485.70 Cr.716 Cr.
Other Operating Expenses675.60 Cr.463.40 Cr.446.10 Cr.469.40 Cr.
Interest Expense-17.70 Cr.-8.80 Cr.-17.70 Cr.-16.20 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense32.20 Cr.137.20 Cr.110.60 Cr.182.30 Cr.
Total Revenue1944.80 Cr.2056.10 Cr.1915 Cr.2094.50 Cr.
Total Operating Expenses1823.90 Cr.1562.80 Cr.1429.30 Cr.1378.50 Cr.
Cost of Revenue560.90 Cr.531.80 Cr.406 Cr.381.80 Cr.
Total Other Income Expense Net81.30 Cr.86.30 Cr.83 Cr.108.70 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.170 Cr.442.40 Cr.458.10 Cr.642.40 Cr.
Net Income Applicable to Common Shares170 Cr.440.90 Cr.460.80 Cr.644.40 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets82.20 Cr.9.40 Cr.8.80 Cr.8.70 Cr.
Capital Surplus01391.50 Cr.1372.90 Cr.1404.80 Cr.
Total Liabilities845.50 Cr.668.50 Cr.803.10 Cr.812.10 Cr.
Stock Holder Equity4263.60 Cr.4121.60 Cr.3773.50 Cr.3489 Cr.
Minority Interest01.80 Cr.11.20 Cr.2 Cr.
Other Liabilities124.10 Cr.48.40 Cr.56.80 Cr.79.90 Cr.
Total Assets5109.10 Cr.4791.90 Cr.4587.80 Cr.4303.10 Cr.
Common Stock36.50 Cr.36.50 Cr.36.40 Cr.36.50 Cr.
Retained Earnings02627.70 Cr.2298.60 Cr.1996.60 Cr.
Other Liabilities127.10 Cr.142 Cr.116.90 Cr.83.40 Cr.
Good Will50.70 Cr.000
Treasury Stock4227.10 Cr.65.90 Cr.65.60 Cr.51.10 Cr.
Other Assets66.20 Cr.48.60 Cr.76.20 Cr.71.20 Cr.
Cash206.10 Cr.25.80 Cr.19.80 Cr.28.30 Cr.
Current Liabilities710.40 Cr.525.60 Cr.685.30 Cr.728.70 Cr.
Long Term Asset Charges0000
Short Long Term Debt0000
Other Stockholder Equity4227.10 Cr.65.90 Cr.65.60 Cr.51.10 Cr.
Property Plant Equipment2308.40 Cr.2237.20 Cr.2093.60 Cr.1856.10 Cr.
Total Cur. Assets2497.20 Cr.2337.30 Cr.2325.60 Cr.2347.20 Cr.
Long Term Investments104.40 Cr.159.40 Cr.83.60 Cr.19.90 Cr.
Net Tangible Assets4130.70 Cr.4112.20 Cr.3764.70 Cr.3480.30 Cr.
Short Term Investments593.80 Cr.784.40 Cr.882.70 Cr.1029.30 Cr.
Net Receivables631 Cr.498.10 Cr.633.30 Cr.606.80 Cr.
Long Term Debt0000
Inventory762 Cr.910.40 Cr.698.70 Cr.590.80 Cr.
Accounts Payable161.80 Cr.146.20 Cr.255.40 Cr.217 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account